Jonathan P Troost1, Howard Trachtman2, Cathie Spino3, Frederick J Kaskel4, Aaron Friedman5, Marva M Moxey-Mims6, Richard N Fine7, Jennifer J Gassman8, Jeffrey B Kopp9, Liron Walsh10, Rong Wang11, Debbie S Gipson12. 1. Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI. Electronic address: troostj@med.umich.edu. 2. Division of Nephrology, Department of Pediatrics, New York University Langone Health, New York, NY. 3. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI. 4. Division of Pediatric Nephrology, Children's Hospital at Montefiore, Bronx, NY. 5. Division of Nephrology, Department of Pediatrics, University of Minnesota, Minneapolis, MN. 6. Division of Nephrology, Children's National Hospital, Department of Pediatrics, The George Washington University School of Medicine, Washington, DC. 7. Stony Brook University Medical Center, School of Medicine, Stony Brook, NY. 8. Department of Quantitative Health Sciences at the Cleveland Clinic, Cleveland, OH. 9. Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 10. Goldfinch Bio, Cambridge, MA. 11. Pfizer Inc, New York, NY. 12. Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI.
Abstract
RATIONALE & OBJECTIVE: Remission of proteinuria has been shown to be associated with lower rates of kidney disease progression among people with focal segmental glomerulosclerosis (FSGS). The goal of this study was to evaluate whether reductions in proteinuria after treatment are associated with greater kidney survival. STUDY DESIGN: Cohort analysis of clinical trial participants. SETTING & PARTICIPANTS: Patients with steroid-resistant FSGS enrolled in a randomized treatment trial that compared cyclosporine with mycophenolate mofetil plus dexamethasone. PREDICTORS: Reduction in proteinuria measured during 26 weeks after initiating treatment. OUTCOMES: Repeated assessments of estimated glomerular filtration rate (eGFR) and time to a composite outcome of kidney failure or death assessed between 26 weeks and 54 months after randomization. ANALYTICAL APPROACH: Multivariable linear mixed-effects models with participant-specific slope and intercept to estimate the association of change in proteinuria over 26 weeks while receiving treatment with the subsequent slope of change in eGFR. Multivariable time-varying Cox proportional hazards models were used to estimate the association of changes in proteinuria with time to the composite outcome. RESULTS: 138 of 192 trial participants were included. Changes in proteinuria over 26 weeks were significantly related to eGFR slope. A 1-unit reduction in log-transformed urinary protein-creatinine ratio was associated with a 3.90mL/min/1.73m2 per year increase in eGFR (95% CI, 2.01-5.79). This difference remained significant after adjusting for complete remission. There was an analogous relationship between time-varying proteinuria and time to the composite outcome: the HR per 1-unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI, 0.12-0.44). LIMITATIONS: Limited to individuals with steroid-resistant FSGS followed up for a maximum of 5 years. CONCLUSIONS: These findings provide evidence for the benefit of urinary protein reduction in FSGS. Reductions in proteinuria warrant further evaluation as a potential surrogate for preservation of kidney function that may inform the design of future clinical trials.
RATIONALE & OBJECTIVE: Remission of proteinuria has been shown to be associated with lower rates of kidney disease progression among people with focal segmental glomerulosclerosis (FSGS). The goal of this study was to evaluate whether reductions in proteinuria after treatment are associated with greater kidney survival. STUDY DESIGN: Cohort analysis of clinical trial participants. SETTING & PARTICIPANTS: Patients with steroid-resistant FSGS enrolled in a randomized treatment trial that compared cyclosporine with mycophenolate mofetil plus dexamethasone. PREDICTORS: Reduction in proteinuria measured during 26 weeks after initiating treatment. OUTCOMES: Repeated assessments of estimated glomerular filtration rate (eGFR) and time to a composite outcome of kidney failure or death assessed between 26 weeks and 54 months after randomization. ANALYTICAL APPROACH: Multivariable linear mixed-effects models with participant-specific slope and intercept to estimate the association of change in proteinuria over 26 weeks while receiving treatment with the subsequent slope of change in eGFR. Multivariable time-varying Cox proportional hazards models were used to estimate the association of changes in proteinuria with time to the composite outcome. RESULTS: 138 of 192 trial participants were included. Changes in proteinuria over 26 weeks were significantly related to eGFR slope. A 1-unit reduction in log-transformed urinary protein-creatinine ratio was associated with a 3.90mL/min/1.73m2 per year increase in eGFR (95% CI, 2.01-5.79). This difference remained significant after adjusting for complete remission. There was an analogous relationship between time-varying proteinuria and time to the composite outcome: the HR per 1-unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI, 0.12-0.44). LIMITATIONS: Limited to individuals with steroid-resistant FSGS followed up for a maximum of 5 years. CONCLUSIONS: These findings provide evidence for the benefit of urinary protein reduction in FSGS. Reductions in proteinuria warrant further evaluation as a potential surrogate for preservation of kidney function that may inform the design of future clinical trials.
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: Circulation Date: 2018-10-23 Impact factor: 29.690
Authors: Debbie S Gipson; Howard Trachtman; Frederick J Kaskel; Tom H Greene; Milena K Radeva; Jennifer J Gassman; Marva M Moxey-Mims; Ronald J Hogg; Sandra L Watkins; Richard N Fine; Susan L Hogan; John P Middleton; V Matti Vehaskari; Patti A Flynn; Leslie M Powell; Suzanne M Vento; June L McMahan; Norman Siegel; Vivette D D'Agati; Aaron L Friedman Journal: Kidney Int Date: 2011-07-06 Impact factor: 10.612
Authors: Juan Jesús Carrero; Morgan E Grams; Yingying Sang; Johan Ärnlöv; Alessandro Gasparini; Kunihiro Matsushita; Abdul R Qureshi; Marie Evans; Peter Barany; Bengt Lindholm; Shoshana H Ballew; Andrew S Levey; Ron T Gansevoort; Carl G Elinder; Josef Coresh Journal: Kidney Int Date: 2016-12-04 Impact factor: 10.612
Authors: Andrew S Levey; Ron T Gansevoort; Josef Coresh; Lesley A Inker; Hiddo L Heerspink; Morgan E Grams; Tom Greene; Hocine Tighiouart; Kunihiro Matsushita; Shoshana H Ballew; Yingying Sang; Edward Vonesh; Jian Ying; Tom Manley; Dick de Zeeuw; Kai-Uwe Eckardt; Adeera Levin; Vlado Perkovic; Luxia Zhang; Kerry Willis Journal: Am J Kidney Dis Date: 2019-08-28 Impact factor: 8.860
Authors: Aliza Thompson; Kevin Carroll; Lesley A Inker; Jürgen Floege; Vlado Perkovic; Sonia Boyer-Suavet; Rupert W Major; Judith I Schimpf; Jonathan Barratt; Daniel C Cattran; Barbara S Gillespie; Annamaria Kausz; Alex W Mercer; Heather N Reich; Brad H Rovin; Melissa West; Patrick H Nachman Journal: Clin J Am Soc Nephrol Date: 2019-01-11 Impact factor: 8.237
Authors: Jeffrey B Kopp; Cheryl A Winkler; Xiongce Zhao; Milena K Radeva; Jennifer J Gassman; Vivette D D'Agati; Cynthia C Nast; Changli Wei; Jochen Reiser; Lisa M Guay-Woodford; Martin R Pollak; Friedhelm Hildebrandt; Marva Moxey-Mims; Debbie S Gipson; Howard Trachtman; Aaron L Friedman; Frederick J Kaskel Journal: J Am Soc Nephrol Date: 2015-01-08 Impact factor: 10.121
Authors: Debbie S Gipson; Jonathan P Troost; Richard A Lafayette; Michelle A Hladunewich; Howard Trachtman; Crystal A Gadegbeku; John R Sedor; Lawrence B Holzman; Marva M Moxey-Mims; Kalyani Perumal; Frederick J Kaskel; Peter J Nelson; Katherine R Tuttle; Serena M Bagnasco; Marie C Hogan; Katherine M Dell; Gerald B Appel; John C Lieske; Titilayo O Ilori; Christine B Sethna; Fernando C Fervenza; Susan L Hogan; Patrick H Nachman; Avi Z Rosenberg; Larry A Greenbaum; Kevin E C Meyers; Stephen M Hewitt; Michael J Choi; Jeffrey B Kopp; Olga Zhdanova; Jeffrey B Hodgin; Duncan B Johnstone; Sharon G Adler; Carmen Avila-Casado; Alicia M Neu; Sangeeta R Hingorani; Kevin V Lemley; Cynthia C Nast; Tammy M Brady; Laura Barisoni-Thomas; Alessia Fornoni; J Charles Jennette; Daniel C Cattran; Matthew B Palmer; Keisha L Gibson; Heather N Reich; Michele H Mokrzycki; Kamalanathan K Sambandam; Gaston E Zilleruelo; Christoph Licht; Matthew G Sampson; Peter Song; Laura H Mariani; Matthias Kretzler Journal: Clin J Am Soc Nephrol Date: 2015-12-10 Impact factor: 8.237
Authors: Andrew S Levey; Daniel Cattran; Aaron Friedman; W Greg Miller; John Sedor; Katherine Tuttle; Bertram Kasiske; Thomas Hostetter Journal: Am J Kidney Dis Date: 2009-07-03 Impact factor: 8.860
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Andrea L Oliverio; Dorota Marchel; Jonathan P Troost; Isabelle Ayoub; Salem Almaani; Jessica Greco; Cheryl L Tran; Michelle R Denburg; Michael Matheny; Chad Dorn; Susan F Massengill; Hailey Desmond; Debbie S Gipson; Laura H Mariani Journal: Kidney360 Date: 2021-09-27
Authors: An S De Vriese; Jack F Wetzels; Richard J Glassock; Sanjeev Sethi; Fernando C Fervenza Journal: Nat Rev Nephrol Date: 2021-05-20 Impact factor: 28.314
Authors: Kirk N Campbell; Natali Pennese; Andrea Zaffalon; Barbara Magalhaes; Marina Faiella; Dawn J Caster; Jai Radhakrishnan; Vladimir Tesar; Howard Trachtman Journal: Kidney Med Date: 2022-03-24
Authors: David C Wheeler; Niels Jongs; Bergur V Stefansson; Glenn M Chertow; Tom Greene; Fan Fan Hou; Anna Maria Langkilde; John J V McMurray; Peter Rossing; Michal Nowicki; István Wittmann; Ricardo Correa-Rotter; C David Sjöström; Robert D Toto; Hiddo J L Heerspink Journal: Nephrol Dial Transplant Date: 2022-08-22 Impact factor: 7.186
Authors: Jürgen Floege; Keisha L Gibson; Manuel Praga; Jai Radhakrishnan; Heather N Reich; Michiel F Schreuder; Jack F Wetzels; Vladimír Tesař; Marina Vivarelli; Steffen Biechele; Marcello Tonelli Journal: Kidney Int Rep Date: 2022-06-23
Authors: Rodrigo P Silva-Aguiar; Diogo B Peruchetti; Ana Acacia S Pinheiro; Celso Caruso-Neves; Wagner B Dias Journal: Int J Mol Sci Date: 2022-09-24 Impact factor: 6.208